Spectrum Pharmaceuticals Presents Poziotinib Data in Patients with Brain Metastases from the Zenith20 Clinical Trial
June 04, 2021 at 09:00 am EDT
Spectrum Pharmaceuticals, Inc. announced that the ZENITH20 trial has enrolled NSCLC patients with EGFR and HER2 exon 20 insertion mutations. This analysis looked at the results for 284 patients from Cohorts 1, 2 and 3. 36 patients had brain metastases as reviewed by an independent central imaging laboratory from baseline. Brain metastasis occurs frequently in NSCLC, up to 25% of patients, and is associated with short survival. Patients received poziotinib at a dose of 16mg once daily.